Seeking Alpha

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

– Positive preclinical results of the small-diameter ATEV were recently presented at The American Heart Association’s Scientific Sessions 2024 meeting – DURHAM, N.C., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ...
Nasdaq

Shattuck Labs Advances SL-325 Program with IND Filing Anticipated by Q3 2025, Reports Q1 Financial Results

Shattuck Labs, Inc. has announced progress in its SL-325 program, with an Investigational New Drug (IND) filing expected in the third quarter of 2025. The company reported a cash balance of ...
Nasdaq

Humacyte Plans IND Filing for Small-Diameter ATEV Following Positive Preclinical Results in CABG Applications

Humacyte, Inc. announced plans to file an Investigational New Drug (IND) application with the FDA, aiming to conduct first-in-human clinical trials of its small-diameter acellular tissue engineered ...
Seeking Alpha

Exclusive BAC Article: Ernexa Therapeutics; Q1 Of 2026 IND Filing ERNA-101 PROC, Phase 1 Trial Initiation 2026, ERNA-102 For Autoimmune Disorders And Catalysts

IND filing of ERNA-101 for the treatment of patients with platinum-resistant ovarian cancer, expected in Q1 of 2026. Initiation of phase 1 study, using ERNA-101 for the treatment of patients with ...
Morningstar

ResVita Bio Announces Positive FDA Pre-IND Meeting, Advancing RVB-003 Toward IND Filing for Netherton Syndrome in Early 2026

BERKELEY, Calif., Sept. 24, 2025 /PRNewswire/ -- ResVita Bio, a biotechnology company pioneering continuous protein therapy for skin diseases, today announced the successful completion of a ...